KRAS and non-small cell lung carcinoma: Encouraged by these data, a phase III trial (JUNIPER, NCT02152631) to compare abemaciclib with erlotinib has been started in NSCLC patients having KRAS mutations post‐treatment.116 Along with this, inhibitors for focal adhesion kinase (defactinib) have also shown positive results.